Spot Biosystems Launches with $40 Million Financing and World-First Non-Viral Delivery of Full-Length Dystrophin in Animal Models and Human Patients with DMD
Spot Biosystems, a gene therapy company pioneering a novel non-viral extracellular vesicle (EV) delivery platform for genetic medicines, today emerged from stealth with $40 million in venture financing, landmark preclinical research published in Nature Biomedical Engineering, and an ongoing first-in-human (FIH) clinical trial with early results showing potential for successful translation to patients with Duchenne muscular dystrophy (DMD).
